The human impact of PMS

A photo of a baby leaning back in a woman's lap and smiling. The woman is looking down towards the baby and is smiling also.

Early childhood signs

Common signs of PMS include low or weak muscle tone (hypotonia), poor head control and a weak cry.2

Female toddler with a messy ponytail and yellow t-shirt sits at a table and looks intently at her colourful building block creation, showcasing focus and creativity.

Altered brain development

Patients can experience developmental and speech delays, and intellectual disability.2

An image of a baby sitting in a woman's lap and her hands are holding the baby's feet.

Skills regression

Patients might experience intellectual and motor skills regressions during childhood.2

PMS at a glance

An icon of a navy blue globe with an orange stand.

An urgent need to create treatments

PMS affects 1 in every 7,300 people.3

An icon of two strands of RNA next to each other. The strand on the left is navy blue and the strand on the right is orange. Both strand are otherwise identical. They are both gently curved vertical lines with short horizontal lines staggered downwards like the rungs of a ladder.

PMS is a monogenic haploinsufficient disease

It is caused by the insufficiency of one gene, SHANK3, in which a mutation in (or deletion of) one copy of that gene results in PMS.1

An icon of a navy blue brain with an image of a navy blue and orange clock across the centre-bottom area of the brain.

Patients with PMS experience life-long disability impacting both patients and carers

PMS is associated with a variety of symptoms including intellectual disability, developmental delays, autism-spectrum features, seizures, and hypotonia.2

An icon of a navy blue double-helix of DNA tilted on an angle from the top right corner to the bottom left corner. This DNA has a clear circle with an orange outline around it.

PYC’s therapy, PYC-002, represents a potentially disease-modifying therapeutic candidate for patients with PMS

PYC-002 targets the root cause of PMS, SHANK3 protein insufficiency, by restoring SHANK3 protein to healthy levels resulting in the rescue of neuronal function.

An icon of a navy blue and orange clipboard with ticks on it next to a strand of orange DNA.

Drug development stage

PYC-002 is at the IND-enabling stage, with clinical studies anticipated in 2027.

Mechanism of action of PYC-002 for Phelan-McDermid Syndrome

This video provides an overview of Phelan-McDermid Syndrome and the mechanism of action for PYC's candidate PYC-002.

References

  1. Betancur, C. and J.D. Buxbaum, SHANK3 haploinsufficiency: a "common" but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol Autism, 2013. 4(1): p. 17. ↩︎
  2. Landlust, A.M., et al., Parental perspectives on Phelan-McDermid syndrome: Results of a worldwide survey. Eur J Med Genet, 2023. 66(7): p. 104771. ↩︎
  3. Phelan-McDermid syndrome foundation. What is Phelan-McDermid syndrome? Causes, symptoms & treatment [internet]. Florida, USA: Phelan-McDermid syndrome foundation; 2022. Available from: https://pmsf.org/about-pms/ ↩︎
OUR PARTNERS

PYC is proud to partner with: